| |
|
|
|
Westin Boston Waterfront Hotel, 425 Summer Street, Boston, MA 02210, USA
October 6-7, 2014
With the aging of the population, the need for treatments of ocular diseases and disorders has become more important than ever. Increasingly high incidences of age-related macular degeneration (AMD), glaucoma, diabetic retinopathy and ocular inflammatory diseases demand better, more effective and innovative treatments. If we are to maintain the quality of life for this aging population, the preservation of vision is critical. This conference will address targeting of ophthalmic medications and treatments and will provide the latest results in the field, along with novel and emerging targets that hold promise in treating these quality of life threats.
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute |
|
|
Invited Speakers:
|
|
- Leonide Saad, Ph.D., CEO, Alkeus Pharmaceuticals, Inc.
- James Larrick, Ph.D., Founder, Managing Scientific Director, CMO, Panorama Research Institute, Wntgen LLC & Velocity Pharmaceutical Development
- Ian R. Catchpole, Ph.D., Topical BioPharm Discovery Research and Development, Glaxo-Smith Kline
- Elena Feinstein, M.D., Ph.D., CSO, Quark Pharmaceuticals
- Hilde Revets, Ph.D., Senior Research Fellow, Discovery, Ablynx NV
- Sue Washer, President and CEO, Executive, AGTC
- Magali Saint Geniez, Ph.D., Assistant Scientist, Schepens Eye Research Institute; Assistant Professor, Harvard Medical School
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|